For a full list of our laboratory publications and citations, please use one of the following links:

PubMed

Google Scholar

Scopus

Selected Research Articles

Coulthard LG, Hawksworth OA, Li R, Balachandran A, Lee JD, Sepehrband F, Kurniawan N, Jeanes A, Simmons DG, Wolvetang E, Woodruff TM. (2017). Complement C5aR1 Signaling Promotes Polarization and Proliferation of Embryonic Neural Progenitor Cells through PKCζ. Journal of Neuroscience. 37(22):5395-5407.

Wang HA, Lee JD, Lee KM, Woodruff TM*, Noakes PG*. (2017). Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. Skeletal Muscle. 7(1):10. 

Gorelik A, Sapir T, Haffner-Krausz R, Olender T, Woodruff TM, Reiner O. (2017). Developmental activities of the complement pathway in migrating neurons.

Nature Communications. 8:15096.

Lee JD, Kumar V, Fung JN, Ruitenberg MJ, Noakes PG, Woodruff TM. (2017). Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. British Journal of Pharmacology. 174(8):689-699. 

Croker DE, Monk PN, Halai R, Kaeslin G, Schofield Z, Wu MC, Clark RJ, Blaskovich MA, Morikis D, Floudas CA, Cooper MA, Woodruff TM. (2016). Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling.

Immunology & Cell Biology. 94(8):787-95.

Nabizadeh JA, Manthey HD, Steyn FJ, Chen W, Widiapradja A, Md Akhir FN, Boyle GM, Taylor SM, Woodruff TM*, Rolfe BE*. (2016). The Complement C3a Receptor Contributes to Melanoma Tumorigenesis by Inhibiting Neutrophil and CD4+ T Cell Responses. Journal of Immunology. 196(11):4783-92.

Mantovani S, Gordon R, Li R, Christie DC, Kumar V, Woodruff TM. (2016). Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice. Human Molecular Genetics. 25(9):1780-91.

Woodruff TM, Wu MC, Morgan M, Bain NT, Jeanes A, Lipman J, Ting MJ, Boyd AW, Taylor SM, Coulthard MG. (2016). EphA4-Fc treatment reduces ischemia/reperfusion-induced intestinal injury by inhibiting vascular permeability.

Shock. 45(2):184-91.

Lee JY, Lee JD, Phipps S, Noakes PG, Woodruff TM. (2015). Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 12:90.

Brennan FH, Gordon R, Lao HW, Biggins PJ, Taylor SM, Franklin RJ, Woodruff TM, Ruitenberg MJ. (2015). The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury. Journal of Neuroscience. 35(16):6517-31.

Hawksworth OA, Coulthard LG, Taylor SM, Wolvetang EJ, Woodruff TM. (2014).

Complement C5a promotes human embryonic stem cell pluripotency in the absence of FGF2. Stem Cells. 32(12):3278-84.

Mantovani S, Gordon R, Macmaw JK, Pfluger CM, Henderson RD, Noakes PG, McCombe PA, Woodruff TM. (2014). Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood. Journal of Neuroimmunology. 276(1-2):213-8.

Woodruff TM, Lee JD, Noakes PG. (2014). Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. Proc Natl Acad Sci USA. 111(1):E3-4. 

Lee JD, Kamaruzaman NA, Fung JN, Taylor SM, Turner BJ, Atkin JD, Woodruff TM*, Noakes PG*. (2013). Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neuroinflammation. 10:119.

Wu MC, Brennan FH, Lynch JP, Mantovani S, Phipps S, Wetsel RA, Ruitenberg MJ, Taylor SM, Woodruff TM. (2013). The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc Natl Acad Sci USA. 110(23):9439-44.

Denny KJ, Coulthard LG, Jeanes A, Lisgo S, Simmons DG, Callaway LK, Wlodarczyk B, Finnell RH, Woodruff TM, Taylor SM. (2013). C5a receptor signaling prevents folate deficiency-induced neural tube defects in mice. Journal of Immunology. 190(7):3493-9.

Selected Reviews

Hawksworth OA, Li XX, Coulthard LG, Wolvetang EJ, Woodruff TM. (2017). New concepts on the therapeutic control of complement anaphylatoxin receptors.

Molecular Immunology. 89:36-43.

Brennan FH, Lee JD, Ruitenberg MJ, Woodruff TM. (2016). Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions. Seminars in Immunology. 28(3):292-308.

Coulthard LG, Woodruff TM. (2015). Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth.

Journal of Immunology. 194(8):3542-8.

Li R, Coulthard LG, Wu MC, Taylor SM, Woodruff TM. (2013). C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB Journal. 27(3):855-64.